Founded in 2001 and headquartered in Cologne, Germany, Axiogenesis is one of a small number of companies specializing in induced pluripotent stem cell (iPSC) products. The company also has an American subsidiary that was founded in 2014 and is located in Philadelphia, Pennsylvania. Since its launch, the company has grown into a market leader for in vitro models of healthy and diseased cell types and tissue. [Read more…]
Join Axiogenesis for Human iPSC Application Workshop in Cologne (September 7 – 9, 2016)
Recently, Axiogenesis hosted an American symposium titled, “iPSC Derived Cells & Assays Come of Age.” Held on June 13, 2016, in Boston, Massachusetts, the symposium explored the topic of establishing global standards for iPSC-derived cell products. Because the conversation is critical to a wide range of stem cell industry stakeholders, the symposium was well-attended by representatives from across the pharmaceutical, biotechnology, and chemical sectors. Attendees also viewed case studies of iPS cells in drug development decision-making and biomedical research.
To further support this dialog within the global marketplace, Axiogenesis is now hosting Human iPSC Applications Workshop in Cologne, Germany on September 7 – 9, 2016. [Read more…]
Axiogenesis Supports CiPA’s Aim to Improve Current Regulatory Guidances
In 2006, induced pluripotent stem cells (iPSCs) were first introduced by Shinya Yamanaka at Kyoto University in Japan. Yamanaka’s discovery, which earned him the Nobel prize in 2012, enabled the use of human cells in stem cell science, bypassing the use of embryonic stem cells (ESCs). As a result of this advance, one of the most important applications for induced pluripotent stem cells has become their use as predictive technologies to support and streamline drug safety testing. [Read more…]
Top 10 Differentiators for Axiogenesis within the Global iPSC Marketplace
Groundbreaking experimentation in 2006 by Shinya Yamanaka (Kyoto University, Japan) led to the introduction of induced pluripotent stem cells (iPSCs). These are adult cells that are isolated and then reprogrammed into embryonic-like stem cells through the expression of a specific set of embryonic genes. Yamanaka’s discovery, which earned him the Nobel prize in 2012, enabled the use of human cells in stem cell science, bypassing the use of embryonic stem cells (ESCs). Without the ethical problems associated with ESCs, a large and diverse market for human iPSC research tools has emerged.
Founded in 2001 and headquartered in Cologne, Germany, Axiogenesis initially focused on generating mouse embryonic stem cell derived cells and assays. After Yamanaka’s groundbreaking iPSC technology became available, Axiogenesis was the first European company to license and adopt Yamanaka’s iPSC technology in 2010. [Read more…]
Axiogenesis to Host “iPSC Derived Cells & Assays Come of Age” User Symposium on June 13 in Boston, Massachusetts
Scheduled for June 13, 2016, in Boston, Massachusetts, Axiogenesis is hosting an American symposium titled, “iPSC Derived Cells & Assays Come of Age.” Hosted at the Westin Waterfront, the symposium will explore how experts in the pharmaceutical industry and leading academic institutions are using Axiogenesis’ cells and assays in drug discovery, safety/toxicology screening, and bioengineering. It will also present current approaches to establish and define standards for these cellular models.
Expected to be widely attended by representatives from the pharmaceutical sector, symposium attendees will also view case studies of iPS cells in drug development decision-making and biomedical research. [Read more…]